Nucleic Acids as Therapeutic Agents - icaam

More documents

Recommendations

Info

Fig. 11.5 A liposome carrying a nucleic acid. In one experimentused to control psoriasis with an antisense oligo (15 long) vs. IGF-1 receptors. Tested different oligos. Best ones reduced IGF-1receptors by ~50%.
Fig. 11.7 Schematic representation of the reverse transcription of retroviralRNA (red) to produce ds DNA (minus strand is light blue and plus strand isdark blue). Step 1, a tRNA primes synthesis of the minus strand. RNA showsU3 and U5 elements and polypurine tract (PPT). Step 2, a complete RNA-DNAduplex is formed. Step 3, RNase H digests the vRNA in the RNA-DNA duplexinto small pieces. Step 4, ds DNA copy of the vRNA which can exist as aprovirus integrated into a cell’s DNA. To block the formation of the minusstrand and hence the synthesis of a ds DNA version of the virus, an antisenseoligonucleotide that hybridizes to the PPT region is added. This protectsagainst retroviruses in mice.
Page 1 and 2: Nucleic Acids asTherapeutic Agents
Page 3: Fig. 11.1 Inhibition of translation
Page 7 and 8: Thomas Cech and Sidney Altman share
Page 9 and 10: Vascular endothelialgrowth factor
Page 11 and 12: Interfering RNAs• Addition of ds
Page 13 and 14: Fire and Mello shared the 2006 Nobe
Page 15 and 16: Nucleic Acid Delivery
Page 17 and 18: Gene Doping: non-therapeutic use of
Page 19 and 20: Fig. 11.21 Use of a nonpathogenic s
Page 21 and 22: Fig. 11.23 A single chain Fab fragm

Nucleic Acids as Therapeutic Agents - icaam

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?